Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 2/20 | 0.73 |
| ▸ | MAX | P61244 | 2/20 | 0.73 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.70 |
| ▸ | PIM1 | P11309 | 3/20 | 0.70 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.70 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.70 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.70 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.68 |
| ▸ | GSK3B | P49841 | 2/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 1/20 | 0.67 |
| ▸ | CDC7 | O00311 | 1/20 | 0.67 |
| ▸ | PLK4 | O00444 | 1/20 | 0.67 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.67 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.67 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.67 |
| ▸ | PRKCG | P05129 | 1/20 | 0.67 |
| ▸ | CDK1 | P06493 | 1/20 | 0.67 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22492973 | 1.00 | MYC (0.73) | MYCMAXDYRK1APIM1PIM3 | |
| SCHEMBL29376987 | 1.00 | MYC (0.73) | MYCMAXDYRK1APIM1PIM3 | |
| SCHEMBL18095862 | 0.86 | MYC (0.68) | MYCMAXDYRK1APIM1PIM3 | |
| SCHEMBL18095865 | 0.86 | MYC (0.68) | MYCMAXDYRK1APIM1PIM3 | |
| SCHEMBL18103100 | 0.86 | MYC (0.68) | MYCMAXDYRK1APIM1PIM3 | |
| SCHEMBL15421744 | 0.85 | MYC (1.00) | MYCMAXDYRK1APIM1PIM3 | |
| SCHEMBL15421743 | 0.85 | MYC (1.00) | MYCMAXDYRK1APIM1PIM3 | |
| SCHEMBL15421742 | 0.85 | MYC (1.00) | MYCMAXDYRK1APIM1PIM3 | |
| SCHEMBL17397855 | 0.84 | MYC (0.77) | MYCMAXDYRK1APIM1PIM3 | |
| SCHEMBL17397854 | 0.84 | MYC (0.77) | MYCMAXDYRK1APIM1PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590127-B2 | Split photoactive yellow protein complementation system and uses thereof | PARIS SCIENCES ET LETTRES (FR) | 2026-03-31 | — | — | US | disclosed |
| US-20220169682-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | PARIS SCIENCES ET LETTRES (FR) | 2022-06-02 | — | — | US | disclosed |
| EP-3947355-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | Paris Sciences et Lettres (FR) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020201538-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | PARIS SCIENCES ET LETTRES – QUARTIER LATIN (FR) | 2020-10-08 | — | — | WO | disclosed |
| EP-3719007-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169682-A1 | SPLIT PHOTOACTIVE YELLOW PROTEIN COMPLEMENTATION SYSTEM AND USES THEREOF | BLVRB, IK, HBG2 | MYC 1462/4885MAX 118/4885DYRK1A 75/4885 |
| US-12590127-B2 | Split photoactive yellow protein complementation system and uses thereof | BLVRB, HBG2, Q6ZSR9 | MYC 1156/4885MAX 81/4885DYRK1A 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.